Astrazeneca Plc (NYSE:AZN) Receives $205.33 Average Target Price from Analysts

Shares of Astrazeneca Plc (NYSE:AZN) have been assigned an average rating of “Moderate Buy” from the thirteen research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and twelve have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $205.3333.

AZN has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a report on Thursday, May 14th. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Citigroup assumed coverage on Astrazeneca in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, May 13th.

More Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca and Daiichi Sankyo won FDA approval for Enhertu in two additional early-stage HER2-positive breast cancer settings, expanding the drug’s addressable market and strengthening the company’s oncology pipeline. AZN, Daiichi’s Enhertu Gets FDA Nod for Two New Breast Cancer Settings
• Positive Sentiment: The FDA also approved Baxfendy (baxdrostat), AstraZeneca’s first-in-class hypertension drug, which could become a meaningful new growth driver in a large cardiovascular market and may support expectations for multibillion-dollar peak sales. AstraZeneca’s blood pressure drug wins U.S. approval
• Neutral Sentiment: Some commentary on the FDA wins raised questions about valuation and the pace of long-term growth, suggesting investors may balance the near-term enthusiasm against execution and pricing concerns. AstraZeneca’s New FDA Wins Raise Questions On Growth And Valuation
• Neutral Sentiment: Erste Group Bank slightly lowered its FY2026 EPS estimate for AstraZeneca to $10.17 from $10.25, though that remains close to the consensus of $10.26 and does not materially change the earnings outlook.

Astrazeneca Price Performance

Astrazeneca stock opened at $184.69 on Friday. The business’s 50-day simple moving average is $191.97 and its 200 day simple moving average is $182.43. The stock has a market cap of $286.44 billion, a price-to-earnings ratio of 27.73, a P/E/G ratio of 1.51 and a beta of 0.26. Astrazeneca has a 12-month low of $137.23 and a 12-month high of $212.71. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. As a group, research analysts anticipate that Astrazeneca will post 10.25 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its holdings in Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after buying an additional 1,461,786 shares in the last quarter. Fisher Asset Management LLC lifted its position in shares of Astrazeneca by 2.1% during the 4th quarter. Fisher Asset Management LLC now owns 21,601,433 shares of the company’s stock valued at $3,791,051,000 after acquiring an additional 438,709 shares during the period. Franklin Resources Inc. lifted its position in shares of Astrazeneca by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 20,157,744 shares of the company’s stock worth $3,537,684,000 after buying an additional 445,014 shares during the last quarter. Amundi lifted its position in shares of Astrazeneca by 146,574.4% during the 1st quarter. Amundi now owns 15,386,149 shares of the company’s stock worth $3,034,456,000 after buying an additional 15,375,659 shares during the last quarter. Finally, Morgan Stanley lifted its position in shares of Astrazeneca by 3.2% during the 4th quarter. Morgan Stanley now owns 13,878,726 shares of the company’s stock worth $2,435,716,000 after buying an additional 432,939 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.